Capsule endoscopy (CE), introduced in 2000 and FDA-approved in 2001, remains a valuable tool for diagnosing gastrointestinal (GI) lesions, particularly in areas inaccessible to traditional endoscopy. While CE offers non-invasive imaging and improves detection of small bowel diseases and obscure GI bleeding, its widespread use is hindered by limitations such as lack of therapeutic capabilities, inability to obtain biopsies, reliance on peristalsis for movement, and time-consuming image interpretation.
Trending
- ‘Tremendous implications’: Hospital affiliation linked to higher-cost care (Healio)
- Omada Health Launches AI-Powered Meal Map to Transform Nutrition for Cardiometabolic Patients (HIT Consultant)
- 10 Must-Read Posts in GI Oncology This Week (OncoDaily)
- SCA Health expands GI footprint, physician network in 2025 (Becker’s GI & Endoscopy)
- 7 key numbers on the state of GI in 2025 (Becker’s GI & Endoscopy)
- White House Unveils ‘TrumpRx’ Drug-Buying Site and a Pfizer Pricing Deal (The Wall Street Journal)
- CADe for Colonoscopy: Positive and Negative Takeaways From Largest Real-World Study (GI & Endoscopy News)
- FDA OKs Tremfya for Ulcerative Colitis (GI & Hepatology News)